Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/101793
PIRA download icon_1.1View/Download Full Text
Title: Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy
Authors: Zhang, G
Weng, H
Li, Y
Li, P
Gong, Y
Chen, J
Wei, L
Zeng, L
Zeng, Y
Cheng, AS 
Issue Date: Aug-2022
Source: Asia-Pacific Journal of Oncology Nursing, Aug. 2022, v. 9, no. 8, 100103
Abstract: Objective: The aims of this study were to examine the symptom severity and interference among patients with lung cancer treated with PD-1 immunotherapy, explore whether those symptoms were clustered together, and identify factors associated with symptom clusters.
Methods: A cross-sectional study was conducted. Data were collected by demographic and clinical characteristic questionnaires and the M.D. Anderson Symptom Inventory Lung Cancer Module. Symptom clusters were identified using exploratory factor analysis, and stepwise linear regression was applied to analyze the factors affecting the symptom clusters.
Results: A total of 148 patients with lung cancer treated with PD-1 immunotherapy participated in this study. The overall symptom burdens of these patients were mainly at a mild level. The patient symptom clusters identified in this study were a general cluster, a treatment-related cluster, a pulmonary cluster, a gastrointestinal cluster, and a neural cluster. The patients’ Karnofsky performance status (KPS) score (β ​= ​−2.758, P ​< ​0.001) and having a history of chemotherapy (β ​= ​4.384, P ​= ​0.001) were significant predictors of the general cluster. Their KPS scores (β ​= ​−1.202, P ​< ​0.001) and having a history of chemotherapy (β ​= ​−1.957, P ​= ​0.001) were significant predictors of the pulmonary cluster. Their monthly income (β ​= ​−0.316, P ​= ​0.030) and KPS scores (β ​= ​−0.357, P ​= ​0.045) were significant predictors of the gastrointestinal cluster. Having a history of chemotherapy (β ​= ​1.868, P ​< ​0.001) was the predictor of the neural cluster.
Conclusions: The symptom burdens of patients with lung cancer and treated with PD-1 immunotherapy were at a mild level and appeared to be clustered. In addition, because the symptoms that comprise a cluster are interrelated, the diagnosis and management of each symptom in a cluster should not be performed in isolation, and each symptom in a cluster should be treated either simultaneously or in an orderly manner.
Keywords: Lung cancer
Programmed death-1 immunotherapy
Symptom cluster
Publisher: Elsevier BV
Journal: Asia-Pacific journal of oncology nursing 
ISSN: 2347-5625
EISSN: 2349-6673
DOI: 10.1016/j.apjon.2022.100103
Rights: © 2022 The Author(s). Published by Elsevier Inc. on behalf of Asian Oncology Nursing Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The following publication Zhang, G., Weng, H., Li, Y., Li, P., Gong, Y., Chen, J., ... & Cheng, A. S. (2022). Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy. Asia-Pacific Journal of Oncology Nursing, 9(8), 100103 is available at https://doi.org/10.1016/j.apjon.2022.100103.
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
1-s2.0-S2347562522001615-main.pdf327.89 kBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show full item record

Page views

131
Last Week
2
Last month
Citations as of Nov 9, 2025

Downloads

88
Citations as of Nov 9, 2025

SCOPUSTM   
Citations

10
Citations as of Dec 19, 2025

WEB OF SCIENCETM
Citations

9
Citations as of Dec 18, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.